574 Appendices 331. Chou CK, Chen RF, Chou FF, Chang HW, Chen YJ, Lee YF, et al. miR-146b is highly expressed in adult papillary thyroid carcinomas with high risk features including extrathyroidal invasion and the BRAF(V600E) mutation. Thyroid. 2010;20:489-494. https://doi.org/10.1089/thy.2009.0027. 332. National Cancer Institute. The website of the National Cancer Institute. https://www.cancer.gov. 333. Cancer Genome Atlas Research N. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014;159:676-690. https://doi.org/10.1016/j.cell.2014.09.050. 334. Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY, et al. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. The New England journal of medicine. 2015;373:726-736. https://doi.org/10.1056/ NEJMoa1502309. 335. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. The New England journal of medicine. 2011;364:2507-2516. https://doi. org/10.1056/NEJMoa1103782. 336. Pagan M, Kloos RT, Lin CF, Travers KJ, Matsuzaki H, Tom EY, et al. The diagnostic application of RNA sequencing in patients with thyroid cancer: an analysis of 851 variants and 133 fusions in 524 genes. BMC Bioinformatics. 2016;17 Suppl 1:6. https://doi.org/10.1186/s12859-015-0849-9. 337. Ciregia F, Giusti L, Molinaro A, Niccolai F, Agretti P, Rago T, et al. Presence in the pre-surgical fine-needle aspiration of potential thyroid biomarkers previously identified in the post-surgical one. PloS one. 2013;8:e72911. https://doi. org/10.1371/journal.pone.0072911. 338. Pagni F, Mainini V, Garancini M, Bono F, Vanzati A, Giardini V, et al. Proteomics for the diagnosis of thyroid lesions: preliminary report. Cytopathology. 2014. https://doi.org/10.1111/cyt.12166. 339. Cerutti JM, Oler G, Delcelo R, Gerardt R, Michaluart P, Jr., de Souza SJ, et al. PVALB, a new Hurthle adenoma diagnostic marker identified through gene expression. The Journal of clinical endocrinology and metabolism. 2011;96:E151-160. https://doi.org/10.1210/jc.2010-1318. 340. Evangelisti C, de Biase D, Kurelac I, Ceccarelli C, Prokisch H, Meitinger T, et al. A mutation screening of oncogenes, tumor suppressor gene TP53 and nuclear encoded mitochondrial complex I genes in oncocytic thyroid tumors. BMC cancer. 2015;15:157. https://doi.org/10.1186/s12885-015-1122-3. 341. Finley DJ, Zhu B, Fahey TJ, 3rd. Molecular analysis of Hurthle cell neoplasms by gene profiling. Surgery. 2004;136:11601168. https://doi.org/10.1016/j.surg.2004.05.061. 342. Ganly I, Ricarte Filho J, Eng S, Ghossein R, Morris LG, Liang Y, et al. Genomic dissection of Hurthle cell carcinoma reveals a unique class of thyroid malignancy. The Journal of clinical endocrinology and metabolism. 2013;98:E962972. https://doi.org/10.1210/jc.2012-3539. 343. Corver WE, Ruano D, Weijers K, den Hartog WC, van Nieuwenhuizen MP, de Miranda N, et al. Genome haploidisation with chromosome 7 retention in oncocytic follicular thyroid carcinoma. PloS one. 2012;7:e38287. https://doi. org/10.1371/journal.pone.0038287. 344. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement. PLoS Med. 2009;6:e1000097. https://doi.org/10.1371/journal.pmed.1000097. 345. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Annals of internal medicine. 2003;138:W1-12. 346. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Annals of internal medicine. 2011;155:529-536. https://doi. org/10.7326/0003-4819-155-8-201110180-00009. 347. Dwamena B. MIDAS: Stata module for meta-analytical integration of diagnostic test accuracy studies. Statistical Software Components S456880, Boston College Department of Economics. 2007;revised 05 Feb 2009. 348. Harbord RM. metandi: Meta-analysis of diagnostic accuracy using hierarchical logistic regression. The Stata Journal. 2009;9:211-229. 349. StataCorp. Stata Statistical Software: Release 14. College Station, TX: StataCorp LP; 2015. 350. Park SJ, Sun JY, Hong K, Kwak JY, Kim EK, Chung WY, et al. Application of BRAF, NRAS, KRAS mutations as markers for the detection of papillary thyroid cancer from FNAB specimens by pyrosequencing analysis. Clinical chemistry and laboratory medicine. 2013;51:1673-1680. https://doi.org/10.1515/cclm-2012-0375. 351. Giovanella L, Campenni A, Treglia G, Verburg FA, Trimboli P, Ceriani L, et al. Molecular imaging with (99m)Tc-MIBI and molecular testing for mutations in differentiating benign from malignant follicular neoplasm: a prospective comparison. Eur J Nucl Med Mol Imaging. 2016;43:1018-1026. https://doi.org/10.1007/s00259-015-3285-1. 352. Trimboli P, Guglielmi R, Monti S, Misischi I, Graziano F, Nasrollah N, et al. Ultrasound sensitivity for thyroid malignancy is increased by real-time elastography: a prospective multicenter study. The Journal of clinical endocrinology and metabolism. 2012;97:4524-4530. https://doi.org/10.1210/jc.2012-2951.
RkJQdWJsaXNoZXIy MTk4NDMw